FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1827702065> ?p ?o ?g. }

• W1827702065 endingPage "3505" @default.
• W1827702065 startingPage "3505" @default.
• W1827702065 abstract "3505 Background: Doublets plus bev are a standard option for the first-line treatment of mCRC. First-line FOLFOXIRI demonstrated superior RR, PFS and OS compared to FOLFIRI. A phase II study of FOLFOXIRI/bev showed promising activity and manageable toxicities. The objective of the TRIBE trial was to confirm the superiority of FOLFOXIRI vs FOLFIRI when bev is added to chemotherapy (CT). Methods: Eligibility criteria included: measurable and unresectable mCRC, age 18-75 years, no prior CT for advanced disease. Pts were randomized to either FOLFIRI/bev (arm A) or FOLFOXIRI/bev (arm B). Both treatments were administered for a maximum of 12 cycles followed by 5FU/bev until progression. Primary endpoint was PFS. Results: Between July 2008 and May 2011 508 pts were randomized. Pts characteristics were (arm A/arm B): median age 60/61, ECOG PS 1-2 11%/10%, synchronous metastases 81%/79%, multiple sites of disease 74%/70%, liver-only disease 18%/23%, prior adjuvant (adj) 12%/12%. At a median follow-up of 26.6 mos 424 pts progressed and 244 died. Median PFS and OS in the intention to treat (ITT) population were 10.9 and 30.9 mos. FOLFOXIRI/bev significantly increased PFS (median 9.7 vs 12.2 mos, HR 0.73 [0.60-0.88] p=0.0012). Subgroup analyses based on stratification factors (PS, prior adj) and baseline characteristics (site of primary, liver only disease, resection of primary, Kohne score) did not evidence significant interactions between treatment and analyzed factors. A trend toward a more consistent effect of FOLFOXIRI/bev was reported in no prior adj (HR 0.68 [0.55-0.83]) compared to prior adj group (HR 1.18 [0.67-2.08], p for interaction=0.071). Response rate (RECIST) was also significantly improved (53% vs 65% p=0.006). FOLFOXIRI/bev did not increase the R0 secondary resection rate in the ITT population (12% vs 15%, p=0.327), or in the liver-only subgroup (28% vs 32%, p=0.823). Conclusions: FOLFOXIRI/bev compared to FOLFIRI/bev, significantly increases PFS and response rate. Subgroup analysis suggests a possible interaction between prior adj CT and PFS benefit. Secondary resection rate does not differ between treatment arms. Clinical trial information: NCT00719797." @default.
• W1827702065 created "2016-06-24" @default.
• W1827702065 creator A5012034272 @default.
• W1827702065 creator A5013554030 @default.
• W1827702065 creator A5015936724 @default.
• W1827702065 creator A5024088672 @default.
• W1827702065 creator A5026748433 @default.
• W1827702065 creator A5034356923 @default.
• W1827702065 creator A5038784620 @default.
• W1827702065 creator A5045260424 @default.
• W1827702065 creator A5050114898 @default.
• W1827702065 creator A5051613962 @default.
• W1827702065 creator A5054413273 @default.
• W1827702065 creator A5055683935 @default.
• W1827702065 creator A5056207263 @default.
• W1827702065 creator A5058514609 @default.
• W1827702065 creator A5058657353 @default.
• W1827702065 creator A5059367989 @default.
• W1827702065 creator A5068999228 @default.
• W1827702065 creator A5080826945 @default.
• W1827702065 creator A5081985776 @default.
• W1827702065 creator A5084106899 @default.
• W1827702065 date "2013-05-20" @default.
• W1827702065 modified "2023-10-16" @default.
• W1827702065 title "FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group." @default.
• W1827702065 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.3505" @default.
• W1827702065 hasPublicationYear "2013" @default.
• W1827702065 type Work @default.
• W1827702065 sameAs 1827702065 @default.
• W1827702065 citedByCount "43" @default.
• W1827702065 countsByYear W18277020652013 @default.
• W1827702065 countsByYear W18277020652014 @default.
• W1827702065 countsByYear W18277020652015 @default.
• W1827702065 countsByYear W18277020652016 @default.
• W1827702065 countsByYear W18277020652018 @default.
• W1827702065 countsByYear W18277020652020 @default.
• W1827702065 countsByYear W18277020652021 @default.
• W1827702065 countsByYear W18277020652022 @default.
• W1827702065 crossrefType "journal-article" @default.
• W1827702065 hasAuthorship W1827702065A5012034272 @default.
• W1827702065 hasAuthorship W1827702065A5013554030 @default.
• W1827702065 hasAuthorship W1827702065A5015936724 @default.
• W1827702065 hasAuthorship W1827702065A5024088672 @default.
• W1827702065 hasAuthorship W1827702065A5026748433 @default.
• W1827702065 hasAuthorship W1827702065A5034356923 @default.
• W1827702065 hasAuthorship W1827702065A5038784620 @default.
• W1827702065 hasAuthorship W1827702065A5045260424 @default.
• W1827702065 hasAuthorship W1827702065A5050114898 @default.
• W1827702065 hasAuthorship W1827702065A5051613962 @default.
• W1827702065 hasAuthorship W1827702065A5054413273 @default.
• W1827702065 hasAuthorship W1827702065A5055683935 @default.
• W1827702065 hasAuthorship W1827702065A5056207263 @default.
• W1827702065 hasAuthorship W1827702065A5058514609 @default.
• W1827702065 hasAuthorship W1827702065A5058657353 @default.
• W1827702065 hasAuthorship W1827702065A5059367989 @default.
• W1827702065 hasAuthorship W1827702065A5068999228 @default.
• W1827702065 hasAuthorship W1827702065A5080826945 @default.
• W1827702065 hasAuthorship W1827702065A5081985776 @default.
• W1827702065 hasAuthorship W1827702065A5084106899 @default.
• W1827702065 hasConcept C121608353 @default.
• W1827702065 hasConcept C126322002 @default.
• W1827702065 hasConcept C141071460 @default.
• W1827702065 hasConcept C143998085 @default.
• W1827702065 hasConcept C168563851 @default.
• W1827702065 hasConcept C203092338 @default.
• W1827702065 hasConcept C2776694085 @default.
• W1827702065 hasConcept C2776705615 @default.
• W1827702065 hasConcept C2777802072 @default.
• W1827702065 hasConcept C2780259306 @default.
• W1827702065 hasConcept C526805850 @default.
• W1827702065 hasConcept C71924100 @default.
• W1827702065 hasConcept C90924648 @default.
• W1827702065 hasConceptScore W1827702065C121608353 @default.
• W1827702065 hasConceptScore W1827702065C126322002 @default.
• W1827702065 hasConceptScore W1827702065C141071460 @default.
• W1827702065 hasConceptScore W1827702065C143998085 @default.
• W1827702065 hasConceptScore W1827702065C168563851 @default.
• W1827702065 hasConceptScore W1827702065C203092338 @default.
• W1827702065 hasConceptScore W1827702065C2776694085 @default.
• W1827702065 hasConceptScore W1827702065C2776705615 @default.
• W1827702065 hasConceptScore W1827702065C2777802072 @default.
• W1827702065 hasConceptScore W1827702065C2780259306 @default.
• W1827702065 hasConceptScore W1827702065C526805850 @default.
• W1827702065 hasConceptScore W1827702065C71924100 @default.
• W1827702065 hasConceptScore W1827702065C90924648 @default.
• W1827702065 hasIssue "15_suppl" @default.
• W1827702065 hasLocation W18277020651 @default.
• W1827702065 hasOpenAccess W1827702065 @default.
• W1827702065 hasPrimaryLocation W18277020651 @default.
• W1827702065 hasRelatedWork W1792988773 @default.
• W1827702065 hasRelatedWork W2007060363 @default.
• W1827702065 hasRelatedWork W2029464197 @default.
• W1827702065 hasRelatedWork W2417717847 @default.
• W1827702065 hasRelatedWork W2590977625 @default.
• W1827702065 hasRelatedWork W2601923086 @default.
• W1827702065 hasRelatedWork W2610384061 @default.
• W1827702065 hasRelatedWork W2617055067 @default.
• W1827702065 hasRelatedWork W2732470776 @default.

• next